Patients with Reye's syndrome who have been given aspirin are said to maintain higher-than-anticipated salicylate concentrations in blood, for longer than expected. We explored 
Despite clinical observations in Reye's syndrome of salicylate concentrations that are inappropriately high for the doses given and that persist beyond the expected clearance time, a primary role for aspirin in the syndrome has not been seriously entertained, for several reasons. These include (a) there is no history of exposure or detectable salicylate in more than one-third of the cases (1); (b) there are differences in hepatic pathology in aspirin toxicity from that in the syndrome:
focal necrosis, cellular "unrest,"
ballooning, and eosinophilic degeneration without prominent fatty change (2); and (c) salicylate toxicity can be reversed by increasing fluid and alkalinizing the urine or by using peritoneal dialysis (3), in contrast to Reye's syndrome, where fluid restriction appears to be critical and peritoneal dialysis is apparently contraindicated (4 of the impact of the latter study requires that the test used for measuring salicylate be highly specific. Thus, we designed this study to determine the specificity of the Trinder method (9). Also, salicylates being known to bind to serum proteins, we also studied the effect of salicylate on the binding of a fatty acid, palmitate, in Reye's syndrome.
Materials and Methods
The test widely used for salicylates depends on formation of a ferric ion-salicylate complex, which absorbs light at 500-550 nm (9) . Ferric ion, however, is known to complex with many other compounds, particularly phenols and auphatic enols, and some of these complexes absorb light at this end of the visible range (10) .
We screened 131 organic acids, amines, and other compounds for development of visible color when treated with an acidic 100 g/L solution of FeC13. About half of them gave colors ranging from deep yellow to purple. Of such compounds, we prepared 0.2 g/L aqueous solutions, treated them with Trinder's reagent to determine their equivalent "salicylate" content, and measured their absorbance at 540 nm with a spectrophotometer (Gilford Instrument Laboratories, Oberlin, OH 44074).
For thin-layer chromatographic separation of sera we used cellulose pre-coated plastic sheets (Brinkmann Instruments, Inc., Westbury, NY 11590; Polygram Cel 300 PE 1, cellulose MN 300 polyethyleneimine impregnated). Binding studies. Specimens of serum from patients, survivors of Reye's syndrome, and control subjects were extensively dialyzed with a 1000-fold volume of Krebs-Ringer buffer (11) at 4 #{176}C, two times. Samples containing 100 g of protein were diluted to identical volumes and exposed to 1 and 0.5 mmol of [16-'4C}palmitate (0.03 pCi), with and without salicylate (1.5 mmol/L). After the samples had stood for 3 h (at 4#{176}C, to minimize proteolysis) they were washed over a 0.45-gm (av pore size) filter ( 
